EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist

A-Ram Kim iD, Seong-Gak Jeon, So-Jung Park, Byoung-Kook Kim, Mi-Na Kweon, Myoung Ho Jang, Bo-Gie Yang iD

Nutrients · 2026

DOI: 10.3390/nu18071050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nutrients, 2026. Verfasst von A-Ram Kim und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute, GI Longevity Inc., Seongnam 13201, Republic of Korea. Hauptthemen laut MEDLINE: Probiotics, Glucagon-Like Peptide-1 Receptor Agonists, Glucagon-Like Peptides, Energy Metabolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Korea Health Industry Development Institute, Korea Health Industry Development Institute https://ror.org/00fdzyk40.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective treatments for obesity, but substantial weight regain is common after therapy is discontinued. This study investigated whether probiotic strains with anti-obesity effects could enhance GLP-1RA-induced weight loss and attenuate post-treatment weight rebound.

Methods

Candidate lactic acid bacteria were screened for anti-obesity efficacy in a high-fat-diet (HFD)-induced obese mouse model, and the selected strain was further characterized using metabolomic profiling of culture supernatants. To examine its interaction with GLP-1RA therapy, obese mice received dulaglutide for 4 weeks and were monitored for 2 weeks after treatment withdrawal, while the probiotic was orally administered for a total of 6 weeks. Body weight, glycemic parameters, and muscle strength were assessed throughout the study.

Results

Limosilactobacillus fermentum GB102 reduced body weight and improved glycemic control in HFD-fed mice. These metabolic benefits were associated with alterations in circulating metabolic hormones, including adipokines, along with attenuated inflammatory responses in adipose tissue. Metabolomic profiling revealed that GB102 produced high levels of succinic acid, a metabolite previously linked to thermogenic activation. This strain increased whole-body energy expenditure in HFD-fed mice, produced glutamine, and showed enhanced conversion of arginine into ornithine and citrulline. When combined with dulaglutide, GB102 enhanced weight loss, preserved muscle strength, and attenuated both weight regain and glycemic rebound following dulaglutide withdrawal.

Conclusions

These findings suggest that energy-metabolism-enhancing probiotics such as GB102 may enhance the metabolic effects of GLP-1RA therapy and help attenuate weight regain after treatment discontinuation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesEnergy MetabolismObesityImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsAnimalsMaleDiet, High-FatMiceMice, Inbred C57BLWeight LossBlood GlucoseGlucagon-Like Peptide-1 ReceptorDisease Models, AnimalWeight Gain

Stichwörter der Autor:innen

GLP-1 receptor agonistLimosilactobacillus fermentum GB102dulaglutideenergy expenditureobesityprobioticssuccinic acidweight regain

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesdulaglutideImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsBlood GlucoseGlucagon-Like Peptide-1 Receptor

Autor:innen und Institutionen

  • Research Institute, GI Longevity Inc., Seongnam 13201, Republic of Korea.
  • Mediogen Inc., Jecheon 27159, Republic of Korea.
  • Mucosal Immunology Laboratory, Department of Convergence Medicine, University of Ulsan College of Medicine/Asan Medical Center, Seoul 05505, Republic of Korea.
  • Digestive Diseases Research Center, University of Ulsan College of Medicine/Asan Medical Center, Seoul 05505, Republic of Korea.
  • World Premier International Immunology Frontier Research, Osaka University, Suita 565-0871, Japan.
  • Research Institute, GI Innovation Inc., Seoul 05855, Republic of Korea.

ORCID-Profile: A-Ram Kim, Bo-Gie Yang

Förderung

  • Korea Health Industry Development Institute
  • Korea Health Industry Development Institute https://ror.org/00fdzyk40

Zitieren

APA

Kim, A. R., Jeon, S. G., Park, S. J., Kim, B. K., Kweon, M. N., Jang, M. H., & Yang, B. G. (2026). Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist. Nutrients. https://doi.org/10.3390/nu18071050

Vancouver

Kim AR, Jeon SG, Park SJ, Kim BK, Kweon MN, Jang MH, et al. Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist. Nutrients. 2026. doi:10.3390/nu18071050

BibTeX
@article{Kim2026,
  author = {Kim, A-Ram and Jeon, Seong-Gak and Park, So-Jung and Kim, Byoung-Kook and Kweon, Mi-Na and Jang, Myoung Ho and Yang, Bo-Gie},
  title = {Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist},
  journal = {Nutrients},
  year = {2026},
  doi = {10.3390/nu18071050}
}
Kostenlos starten →